New approaches for identifying and testing potential new anti-asthma agents

References

• Global Initiative for Asthma. GINA guidelines. Global strategy for Asthma Management and Prevention. cited 2017 Oct 17. Available at http://www.ginasthma.org/
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Tosca MA, Silvestri M, et al. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Rev Clin Immunol. 2017;13:715–721.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45–56.
   PubMed Web of Science ®Google Scholar
• Hirose K, Iwata A, Tamachi T, et al. Allergic airway inflammation: key players beyond the Th2 cell pathway. Immunol Rev. 2017;278:145–161.
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47:161–175.
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459–465.
   PubMed Web of Science ®Google Scholar
• Palomares Ó, Sánchez-Ramón S, Dávila I, et al. dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. Int J Mol Sci 2017;18. pii: E1328.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10:1033–1042.
   PubMed Web of Science ®Google Scholar
• Ishizaka K, Ishizaka T. Identification of IgE. J Allergy Clin Immunol. 2016;137:1646–1650.
   PubMed Web of Science ®Google Scholar
• Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014;14:247–259.
   PubMed Web of Science ®Google Scholar
• Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205–217.
   PubMed Web of Science ®Google Scholar
• Samitas K, Delimpoura V, Zervas E, et al. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev. 2015;24:594–601.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147–1154.
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, et al. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64:1728–1736.
   PubMed Web of Science ®Google Scholar
• Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583–593.
   PubMed Web of Science ®Google Scholar
• European Public Assessment Report (EPAR) for Xolair. EMA. cited 2017 Oct 17. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR/Product_Information/human/000606/WC500057298.pdf .
   Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16:491–502.
   PubMed Web of Science ®Google Scholar
• Genentech. Xolair® (omalizumab) full prescribing information. cited 2017 Oct 17]. Available from: https://www.gene.com/medical-professionals/medicines/xolair.
   Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124:1210–1216.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–1015.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26:551–556.
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42:1224–1233.
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46:856–859.
   PubMed Web of Science ®Google Scholar
• Froidure A, Shen C, Pilette C. Dendritic cells revisited in human allergic rhinitis and asthma. Allergy. 2016;71(2):137–148.
   PubMed Web of Science ®Google Scholar
• Teach SJ. Omalizumab pre-season treatment reduces Fall asthma exacerbations. J Pediatr. 2016;172:224–227.
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788–797.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Mauro M, Russello M, et al. Omalizumab, an anti immunoglobulin E antibody: state of the art. Drug Des Devel Ther. 2014;7:197–207.
   Google Scholar
• Busse W, R B, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–9.e6.
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–567.e4.
   PubMed Web of Science ®Google Scholar
• Janson SL, Solari PG, Trzaskoma B, et al. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol. 2015;114:516–521.
   PubMed Web of Science ®Google Scholar
• Romano C. Omalizumab therapy for children and adolescents with severe allergic asthma. Expert Rev Clin Immunol. 2015;11:1309–1319.
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, et al. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64(12):1780–1787.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378–1386.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–811.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71:1472–1479.
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2.
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–419.
   PubMed Web of Science ®Google Scholar
• Lavaud F, Bonniaud P, Dalphin JC, et al. Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy. 2013;68(6):813–815.
   PubMed Web of Science ®Google Scholar
• Ollé-Monge M, Cruz MJ, Gomez-Ollés S, et al. Effect of anti-IgE in occupational asthma caused by exposure to low molecular weight agents. Allergy. 2017 Apr 25. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, De Sando E, et al. Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert Opin Biol Ther. 2017;17:429–434.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allerg. 2014;44:1371–1385.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138:1051–1059.
   PubMed Web of Science ®Google Scholar
• Nyborg AC, Zacco A, Ettinger R, et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol. 2016;13:391–400.
   PubMed Web of Science ®Google Scholar
• Sheldon E, Schwickart M, Li J, et al. Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study. Adv Ther. 2016;33:225–251.
   PubMed Web of Science ®Google Scholar
• Liour SS, Tom A, Chan YH, et al. Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody. Pediatr Allergy Immunol. 2016;27:446–451.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014;6:243ra85.
   PubMed Web of Science ®Google Scholar
• Harris JM, Maciuca R, Bradley S, et al. Efficacy and safety of quilizumab in adults with allergic asthma inadequately controlled on inhaled Corticosteroids and a Second Controller (COSTA Study). Am J Respir Crit Care Med. 2015;191:A5168.
   Web of Science ®Google Scholar
• Brightbill HD, Lin YL, Lin Z, et al. Quilizumab is an afucosylated humanized anti-M1 prime therapeutic antibody. Clin Anti-Inflamm & Anti-Allergy Drugs. 2014;1:24–31.
   Google Scholar
• Harris JM, Maciuca R, Bradley MS, et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res. 2016;17:29.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ J. 2014;7:32.
   PubMedGoogle Scholar
• Pepper AN, Renz H, Casale TB, et al. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. 2017;5:909–916.
   PubMed Web of Science ®Google Scholar
• Tabatabaian F, Ledford DK, Casale TB. Biologic and new therapies in asthma. Immunol Allergy Clin North Am. 2017;37:329–343.
   PubMed Web of Science ®Google Scholar
• NUCALA® (mepolizumab) prescribing information. cited 2017 Oct 17. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF.
   Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062–1071.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang S, Li DW, et al. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2013;8:e59872.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–993.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133:921–923.
   PubMed Web of Science ®Google Scholar
• CINQAIR® (reslizumab) prescribing information. cited 2017 Oct 17. Available from: http://cinqair.com/pdf/PrescribingInformation.pdf.
   Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366.
   PubMed Web of Science ®Google Scholar
• Saco TV, Pepper AN, Lockey RF. Benralizumab for the treatment of asthma. Expert Rev Clin Immunol. 2017;13:405–413.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086–96.e5.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2:879–890.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting b2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33:14–20.
   PubMed Web of Science ®Google Scholar
• Trivedi A, Pavord ID, Castro M. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. Lancet Respir Med. 2016;4(7):585–592.
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425–437.
   PubMed Web of Science ®Google Scholar
• Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol. 2012;47:261–270.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and eotaxin production. J Clin Invest. 1999;103:779–780.
   PubMed Web of Science ®Google Scholar
• Shirley M. Dupilumab: first global approval. Drugs. 2017;77:1115–1121.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.
   PubMed Web of Science ®Google Scholar
• Sanofi. Long-term safety evaluation of dupilumab in patients with asthma (LIBERTY ASTHMA TRAVERSE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. cited 2017 Oct 17. Available from: https://clinicaltrials.gov/ct2/show/NCT02134028/NLMIdentifier:NCT02134028.
   Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469–479.
   PubMed Web of Science ®Google Scholar
• Chang HY, Nadeau KC. IL-4Rα inhibitor for atopic disease. Cell. 2017;170:222.
   PubMed Web of Science ®Google Scholar
• Han Y, Chen Y, Liu X, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140:888-891.e6.
   Web of Science ®Google Scholar
• Mullard A. FDA approves dupilumab for severe eczema. Nat Rev Drug Discov. 2017;16:305.
   Web of Science ®Google Scholar
• Parulekar AD, Diamant Z, Hanania NA. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med. 2017;23:3–11.
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Kuna P. Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs. 2017;77:1281–1294.
   PubMed Web of Science ®Google Scholar
• Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131:1504–1512.
   PubMed Web of Science ®Google Scholar
• Peinhaupt M, Sturm EM, Heinemann A. Prostaglandins and their receptors in eosinophil function and as therapeutic targets. Front Med (Lausanne). 2017;4:104.
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4:699–707.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50:1700670. https://doi.org/10.1183/13993003.00670-2017.
   PubMed Web of Science ®Google Scholar
• Kuna P, Bjermer L, Tornling G. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther. 2016;10:2759–2770.
   PubMed Web of Science ®Google Scholar
• Mitchell PD, O’Byrne PM. Epithelial-derived cytokines in asthma. Chest. 2017;151:1338–1344.
   PubMed Web of Science ®Google Scholar
• Watson B, Gauvreau GM. Thymic stromal lymphopoietin: a central regulator of allergic asthma. Expert Opin Ther Targets. 2014;18:771–785.
   PubMed Web of Science ®Google Scholar
• Smith SG, Gugilla A, Mukherjee M, et al. Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma. J Allergy Clin Immunol. 2015;135:1594–1602.
   PubMed Web of Science ®Google Scholar
• Harada M, Hirota T, Jodo AI, et al. Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma. Am J Respir Cell Mol Biol. 2011;44:787–793.
   PubMed Web of Science ®Google Scholar
• Semlali A, Jacques E, Koussih L, et al. Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. J Allergy Clin Immunol. 2010;125:844–850.
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174:8183–8190.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22:470–477.
   PubMed Web of Science ®Google Scholar
• Osborne M, Deffebach M. The epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2004;92:3–4.
   PubMed Web of Science ®Google Scholar
• Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185:356–362.
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–323.
   PubMed Web of Science ®Google Scholar
• Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108:1723–1732.
   PubMed Web of Science ®Google Scholar
• Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66:910–917.
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308–1321.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 2017;49. pii: 1602135.
   Web of Science ®Google Scholar
• Samitas K, Zervas E, Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med. 2017;23:48–55.
   PubMed Web of Science ®Google Scholar
• Nakagome K, Matsushita S, Nagata M. Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol. 2012;158:96–102.
   PubMed Web of Science ®Google Scholar
• Cosmi L, Liotta F, Annunziato F. Th17 regulating lower airway disease. Curr Opin Allergy Clin Immunol. 2016;16:1–6.
   PubMed Web of Science ®Google Scholar
• Annunziato F, Romagnani C, The RS. 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135:626–635.
   PubMed Web of Science ®Google Scholar
• Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol. 2011;32:452–460.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis. 2016;10:211–234.
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Sorbello V, Folino A, et al. Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Cli Immunol. 2017;140:395–406.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294–1302.
   PubMed Web of Science ®Google Scholar
• Amgen. Study of efficacy and safety of brodalumab compared with placebo in inadequately controlled asthma subjects with high bronchodilator reversibility. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. cited 2017 Oct 17. Available from: https://clinicaltrials.gov/ct2/show/NCT01902290/NLM identifier:NCT01902290.
   Google Scholar
• Novartis Pharmaceuticals. Safety, tolerability, and efficacy of AIN457 in patients with uncontrolled asthma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. cited 2017 Oct 17. Available from: https://clinicaltrials.gov/ct2/show/NCT01478360/NLM identifier:NCT01478360.
   Google Scholar
• Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011;37:1352–1359.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–558.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42:1097–1103.
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, Norris V, Kelly K, et al. Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils. Pulm Pharmacol Ther. 2014;27:62–69.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322–329.
   PubMed Web of Science ®Google Scholar
• Silva Filho LV, Pinto LA, Stein RT. Use of macrolides in lung diseases: recent literature controversies. J Pediatr (Rio J). 2015;91:S52–60.
   PubMed Web of Science ®Google Scholar
• Woolcock Institute of Medical Research; National Health and Medical Research Council. The AMAZES study: asthma and macrolides: the azithromycin efficacy and safety study (Glebe, Sydney). Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235. [cited 2017 Oct 17]. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83660
   Google Scholar
• Nair P, Martin JG, Cockcroft DC, et al. Airway hyperresponsiveness in asthma: measurement and clinical relevance. J Allergy Clin Immunol Pract. 2017;5:649–59.e2.
   Google Scholar
• Westerhof GA, Coumou H, De Nijs SB, et al. Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol. 2017. pii: S0091-6749(17)30662-0.
   Google Scholar
• Thomson NC. New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma. Expert Opin Pharmacother. 2017;18:283–293.
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Santus P, Blasi F, et al. The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med. 2017;12:12.
   PubMed Web of Science ®Google Scholar
• Guntur VP, Reinero CR. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol. 2012;12(1):68–75.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Chung KF, Caramori G, et al. Kinase inhibitors and airway inflammation. Eur J Pharmacol. 2006;533:118–132.
   PubMed Web of Science ®Google Scholar
• Da Silva AL, Magalhães RF, Branco VC, et al. The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma. Br J Pharmacol. 2016;173:1236–1247.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–1726.
   PubMed Web of Science ®Google Scholar
• Wang K, Tian P, Wang FYY, et al. Assessment of second line treatments for patients with uncontrolled moderate asthma. Int J Clin Exp Med. 2015;8:19476–19480.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–1207.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double- blind, placebo-controlled, parallel-group, active-comparator, randomized trials. Lancet Respir Med. 2015;3:367–376.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DMG, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low to medium dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4:104–113.
   PubMed Web of Science ®Google Scholar
• Ramratnam SK, Bacharier LB, Guilbert TW. Severe asthma in children. J Allergy Clin Immunol Pract. 2017;5(4):889–898.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. A study to evaluate efficacy and safety of tiotropium in children 6 to 11 years old with moderate asthma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. cited 2017 Oct 17. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT01383499/NLMidentifier:NCT01383499.
   Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015;115:211–216.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138:441–450.e8.
   PubMedGoogle Scholar
• Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci (Lond). 2017;131:1723–1735.
   PubMed Web of Science ®Google Scholar
• Bradding P, Af W, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol. 2006;117:1277–1284.
   PubMed Web of Science ®Google Scholar
• Galli SJ. Mast cells and KIT as potential therapeutic targets in severe asthma. N Engl J Med. 2017;376:1983–1984.
   PubMed Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376:1911–1920.
   PubMed Web of Science ®Google Scholar
• Saglani S, Lloyd CM. Novel concepts in airway inflammation and remodelling in asthma. Eur Respir J. 2015;46:1796–1804.
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Rigden HM, Ward JA, et al. The relationship between eosinophilia and airway remodelling in mild asthma. Clin Exp Allergy. 2013;43:1342–1350.
   PubMed Web of Science ®Google Scholar
• Saglani S, Payne DN, Zhu J, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med. 2007;176:858–864.
   PubMed Web of Science ®Google Scholar
• Roth M, Zhong J, Zumkeller C, et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS One. 2013;8:e56015.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83:520–528.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25:475–484.
   PubMed Web of Science ®Google Scholar
• Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014 Nov;162(1Pt A):2–10.
   PubMed Web of Science ®Google Scholar